These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21831650)

  • 1. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
    Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
    Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.
    Hsiao IT; Weng YH; Lin WY; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lu CS; Lin KJ
    Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
    J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
    J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
    Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
    JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan.
    Huang CY; Liu CH; Tsao E; Hsieh CJ; Weng YH; Hsiao IT; Yen TC; Lin KJ; Huang CC
    J Neurol Sci; 2015; 353(1-2):102-6. PubMed ID: 25936253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
    Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
    Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification and discriminative power of
    Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.
    Lin KJ; Weng YH; Wey SP; Hsiao IT; Lu CS; Skovronsky D; Chang HP; Kung MP; Yen TC
    J Nucl Med; 2010 Sep; 51(9):1480-5. PubMed ID: 20720042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
    Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; Ackermann U; O'Keefe G; Jones G; Gong S; Tochon-Danguy H; Kung HF; Masters CL; Skovronsky DM; Rowe CC
    Arch Neurol; 2011 Jul; 68(7):905-12. PubMed ID: 21747030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
    Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
    PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
    Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
    PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deuterated
    Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
    Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [
    Naganawa M; Lim K; Nabulsi NB; Lin SF; Labaree D; Ropchan J; Herold KC; Huang Y; Harris P; Ichise M; Cline GW; Carson RE
    Mol Imaging Biol; 2018 Oct; 20(5):835-845. PubMed ID: 29468404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
    Bohnen NI; Albin RL; Koeppe RA; Wernette KA; Kilbourn MR; Minoshima S; Frey KA
    J Cereb Blood Flow Metab; 2006 Sep; 26(9):1198-212. PubMed ID: 16421508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.
    Lin KJ; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Hsiao IT
    PLoS One; 2013; 8(9):e75952. PubMed ID: 24098749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.
    Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF
    Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
    J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image.
    Kim JS; Cho H; Choi JY; Lee SH; Ryu YH; Lyoo CH; Lee MS
    PLoS One; 2015; 10(7):e0132585. PubMed ID: 26147749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.